Erratum: A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals (Scientific Reports (2012) 2 (280) DOI: 10.1038/srep00280);A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Moriguchi, Hisashi ^a,b   Zhang, Yue ^c   Mihara, Makoto ^a   Sato, Chifumi ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AKR1B10 PROTEIN, HUMAN; ALDEHYDE REDUCTASE; RETINOID; RETINOID X RECEPTOR;

ARTICLE; ENZYMOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; METABOLISM; OXYGEN CONSUMPTION; PATHOLOGY; RETRACTED ARTICLE;

ALDEHYDE REDUCTASE; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; OXYGEN CONSUMPTION; RETINOID X RECEPTORS; RETINOIDS;

EID: 84859755890     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00839     Document Type: Erratum

References (15)

1. Okita, K. et al., A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409-412 (2011).
2. Muto, Y. et al., Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334, 1561-1567 (1996). (Pubitemid 26177483)
3. Okita, K. et al., Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. J Clin Oncol 28, 15s (Suppl: Abstract 4024) (2010).
4. Fukumoto, S. et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 11, 1776-1785 (2005). (Pubitemid 40471839)
5. Penning, T. M. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 11, 1687-1690 (2005). (Pubitemid 40476161)
6. Moriguchi, H., Chung, R. T., Mihara, M. & Sato, C. The generation of human induced pluripotent stem (iPS) cells from liver progenitor cells by only small molecules and the risk for malignant transformations of the cells. ACSC 2, 5-9 (2010).(http://www. jstage. jst. go. jp/browse/acsc/)
7. Balendiran, G. K., Martin, H. J., El-Hawari, Y. & Maser, E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact 178, 134-137 (2009).
8. Crosas, B., Cederlund, E., Torres, D., Jornvall, H., Farres, J., Pares, X. A vertebrate aldo-keto reductase active with retinoids and ethanol. J Biol Chem 276, 19132-19140 (2001).
9. Gallego, O. et al. Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochem J 399, 101-109 (2006). (Pubitemid 44505411)
10. Gallego, O. et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA. 104, 20764-20769 (2007).
11. Ruiz, F. X. et al. Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact 178, 171-177 (2009).
12. Matsushima-Nishiwaki, R., Okuno, M., Takano, Y., Kojima, S., Friedman, S. L., Moriwaki, H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24, 1353-1359 (2003). (Pubitemid 37038825)
13. Tatsukawa, H. et al. Dual induction of caspase 3-and transglutaminasedependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer 10, 4 (2011).
14. Warburg, O. On respiratory impairment in cancer cells. Science 124, 269-270 (1956).
15. Yoshitake, H. et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 17, 1300-1306 (2007). (Pubitemid 350077355)